Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Spero Therapeutics Inc SPRO

Healthcare Biotechnology
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease... see more

Recent & Breaking News (NDAQ:SPRO)

Spero Therapeutics to Participate at the Berenberg Conference USA

GlobeNewswire May 13, 2021

Spero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update

GlobeNewswire May 6, 2021

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 30, 2021

Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

GlobeNewswire April 29, 2021

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 31, 2021

Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update

GlobeNewswire March 11, 2021

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021

GlobeNewswire March 3, 2021

Spero Therapeutics to Present at Investor Conferences in March

GlobeNewswire February 25, 2021

Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial

GlobeNewswire February 5, 2021

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 29, 2021

Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr

GlobeNewswire January 21, 2021

Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer

GlobeNewswire December 17, 2020

Spero Therapeutics Added to the NASDAQ Biotechnology Index

GlobeNewswire December 16, 2020

Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease

GlobeNewswire December 10, 2020

Spero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer

GlobeNewswire December 2, 2020

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 30, 2020

Spero Therapeutics to Present at the Evercore ISI HealthCONx Conference on December 3, 2020

GlobeNewswire November 30, 2020

Spero Therapeutics Announces Third Quarter 2020 Operating Results and Provides Business Update

GlobeNewswire November 5, 2020

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 3, 2020

Spero Therapeutics to Provide Business Update and Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

GlobeNewswire October 29, 2020